Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic

References

• Jalal H, Buchanich JM, Roberts MS, et al. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018 Sept 21;361(6408).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 5thed. (DSM-5). Washington (DC): (APA) APA, editor; 2013.
   Google Scholar
• Hagemeier NE. Introduction to the opioid epidemic: the economic burden on the healthcare system and impact on quality of life. Am J Manag Care. 2018 May;24(10 Suppl):S200–S206.
   PubMed Web of Science ®Google Scholar
• Florence CS, Zhou C, Luo F, et al. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901–906.
   PubMed Web of Science ®Google Scholar
• Ray GT, Mertens JR, Weisner C. The excess medical cost and health problems of family members of persons diagnosed with alcohol or drug problems. Med Care. 2007 Feb;45(2):116–122.
   PubMed Web of Science ®Google Scholar
• Kirson NY, Scarpati LM, Enloe CJ, et al. The economic burden of opioid abuse: updated findings. J Manag Care Spec Pharm. 2017 Apr;23(4):427–445.
   PubMedGoogle Scholar
• The Council of Economic Advisers. The underestimated cost of the opioid crisis. 2017 [cited 2020 July 22]. Available from: https://www.whitehouse.gov/briefings-statements/cea-report-underestimated-cost-opioid-crisis/
   Google Scholar
• Becker WC, Fiellin DA. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 2020;173(1):59–60.
   PubMed Web of Science ®Google Scholar
• The Opioid Response Network. The opioid epidemic and COVID-19: how social determinants of health create differential impacts. 2020 [cited 2020 July 22]. Available from: https://opioidresponsenetwork.org/documents/SDH_OUD-COVID-19.pdf
   Google Scholar
• American Medical Association (AMA). Issue brief: reports of increases in opioidrelated overdose and other concerns during COVID pandemic. 2020 [cited 2020 July 22]. Available from: https://www.ama-assn.org/system/files/2020-07/issue-brief-increases-in-opioid-related-overdose.pdf
   Google Scholar
• Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open. 2020;3(2):e1920622–e1920622.
   PubMed Web of Science ®Google Scholar
• Boyett B. The individualized treatment of opioid use disorder. J Manag Care Spec Pharm. 2019 June;25(6):634–636.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health & Human Services. Facing addiction in America - the surgeon general’s spotlight on opioids. In: Services USDoHH, editor. Washington, DC; 2018.
   Google Scholar
• Ling W, Nadipelli VR, Solem CT, et al. Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study. J Subst Abuse Treat. 2020 Mar;110:1–8.
   PubMed Web of Science ®Google Scholar
• Ruetsch C, Tkacz J, Nadipelli VR, et al. Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes. Am J Manag Care. 2017 June 1;23(6):e172–e179.
   PubMed Web of Science ®Google Scholar
• Lynch FL, McCarty D, Mertens J, et al. Costs of care for persons with opioid dependence in commercial integrated health systems. Addict Sci Clin Pract. 2014 Aug 14;9(1):16.
   PubMedGoogle Scholar
• Ronquest NA, Willson TM, Montejano LB, et al. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018;9:59–78.
   PubMed Web of Science ®Google Scholar
• Madras B, Ahmad NJ, Wen J, et al. and The Prevention, Treatment, and Recovery Working Group of the Action Collaborative on Countering the U.S. Opioid Epidemic. Improving Access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. 2020 [cited 2020 July 22]. Available from: https://nam.edu/improving-access-to-evidence-based-medical-treatment-for-opioid-use-disorder-strategies-to-address-key-barriers-within-the-treatment-system/
   Google Scholar
• Bentzley BS, Barth KS, Back SE, et al. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat. 2015;52:48–57.
   PubMed Web of Science ®Google Scholar
• Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008 Feb;165(2):179–187.
   PubMed Web of Science ®Google Scholar
• Marsch LA, Campbell A, Campbell C, et al. The application of digital health to the assessment and treatment of substance use disorders: the past, current, and future role of the national drug abuse treatment clinical trials network. J Subst Abuse Treat. 2020 Mar;112S:4–11.
   PubMedGoogle Scholar
• Christensen DR, Landes RD, Jackson L, et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964–972.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008 Jan-Feb;11(1):44–47.
   PubMed Web of Science ®Google Scholar
• Premier. Opioid overdoses costing U.S. hospitals an estimated $11 billion annually. 2019 [cited 2020 Jul 28]. Available from: https://www.premierinc.com/newsroom/press-releases/opioid-overdoses-costing-u-s-hospitals-an-estimated-11-billion-annually
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS). Medicare hospital outpatient prospective payment system addendum A, April 2020 file. 2020 [cited 2020 Jul 28]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-For-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates
   Google Scholar
• Centers for Medicare and Medicaid Services (CMS). Physician fee schedule relative value file, April 2020 release (RVU20B). 2020 [cited 2020 July 28]. Available from: https://www.cms.gov/medicaremedicare-fee-service-paymentphysicianfeeschedpfs-relative-value-files/rvu20b
   Google Scholar
• Barbour Jordan S, Jarvis Margaret A, Withers David J. How geisinger dramatically reduced deaths from opioid use disorder. NEJM Catal. 2020 Mar-Apr;1(2):1–20.
   Google Scholar